Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
JENNIFER SPEAR SMITH
Executive Director, Medical Education, Wyeth
(JOHN HALPERN)
Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
Prior to her current position as executive director of medical education for Wyeth, Spear Smith was a CME provider and before that a professor in physiology at Indiana University and Purdue University's combined medical school program. "Medical school was just a starting point for me," says Spear Smith. "Things change so differently in medicine. There is a system, but it needs improvement so that physicians can be helping patients. That is the reason I go to work every day, to improve patient care."
Spear Smith was attracted to the pharma industry for the ample resources available to guide CME in a direction where she could "make a difference in patient care." And she already has by helping to make Wyeth one of the first pharmaceutical companies to require CME providers, after they conducted a CME activity, to measure its success.
"In 10 years, I hope I am still involved in managing education of physicians where it's my goal to continue in a position that ultimately helps patient care," Spear Smith says. "A pharma company is in the perfect position to make a change with how they conduct business and really gear it toward patient care. When we can do that we will have really revolutionized the business."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.